Table 4.
. In vitro susceptibility of multidrug-resistant Enterobacterales collected in six Latin American countriesa divided into two 3-year time periods 2015‒2017 and 2018‒2020.
| Collection years (n) | Compound | Range | MIC50 | MIC90 | CLSI Interpretationb |
||
|---|---|---|---|---|---|---|---|
| (µg/mL) | %S | %I | %R | ||||
| 2015‒2017 (1701) | Amikacin | ≤ 0.25 – > 32 | 4 | 32 | 86.2 | 6.0 | 7.8 |
| Aztreonam | ≤ 0.015 – > 128 | 64 | > 128 | 3.5 | 0.6 | 95.9 | |
| Cefepime | ≤ 0.12 – > 16 | > 16 | > 16 | 3.4 | 4.7 | 91.9 | |
| Ceftazidime | 0.03 – > 128 | 32 | > 128 | 6.8 | 5.6 | 87.5 | |
| Ceftazidime-avibactam | ≤ 0.015 – > 128 | 0.25 | 2 | 97.1 | NA | 2.9 | |
| Colistin | ≤ 0.06 – > 8 | 0.5 | > 8 | NA | 87.3 | 12.7 | |
| Imipenem | 0.06 – > 8 | 0.25 | > 8 | 74.8 | 3.1 | 22.2 | |
| Levofloxacin | ≤ 0.03 – > 8 | > 8 | > 8 | 8.1 | 4.4 | 87.5 | |
| Meropenem | 0.015 – > 8 | 0.06 | > 8 | 76.4 | 2.9 | 20.7 | |
| Piperacillin Tazobactam | ≤ 0.25 – > 128 | 32 | >128 | 32.2 | 8.5 | 59.3 | |
| 2018‒2020 (1838) | Amikacin | 0.5 – > 64 | 4 | 64 | 81.2 | 7.8 | 11.0 |
| Aztreonam | ≤ 0.015 – > 128 | > 64 | > 128 | 5.1 | 0.7 | 94.2 | |
| Cefepime | ≤ 0.12 – > 32 | >32 | > 32 | 2.2 | 4.9 | 92.9 | |
| Ceftazidime | 0.12 – > 128 | 64 | > 128 | 5.4 | 3.6 | 91.0 | |
| Ceftazidime-avibactam | ≤ 0.015 – > 128 | 0.5 | > 64 | 89.3 | NA | 10.7 | |
| Colistin | ≤ 0.06 – > 8 | 0.5 | > 8 | NA | 82.6 | 17.4 | |
| Imipenem | ≤ 0.06 – > 8 | 0.5 | > 8 | 60.6 | 3.2 | 36.2 | |
| Levofloxacin | ≤ 0.25 – > 8 | >8 | > 8 | 8.4 | 6.0 | 85.6 | |
| Meropenem | ≤ 0.06 – > 16 | 0.12 | > 16 | 62.2 | 3.3 | 34.5 | |
| Piperacillin Tazobactam | 0.25 – > 64 | > 64 | > 64 | 26.1 | 8.5 | 65.3 | |
a
Countries included Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela.
b
S, susceptible; I, intermediate; R, resistant.